Cargando…

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus isolates were collected and subjected to susc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Weiliang, Zhang, Xiaotuan, Liu, Yan, Zhang, Yi, Xu, Mengxin, Wang, Sipei, Sun, Yao, Zhou, Tieli, Chen, Lijiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722764/
https://www.ncbi.nlm.nih.gov/pubmed/36483205
http://dx.doi.org/10.3389/fmicb.2022.1043736
_version_ 1784844027727708160
author Zeng, Weiliang
Zhang, Xiaotuan
Liu, Yan
Zhang, Yi
Xu, Mengxin
Wang, Sipei
Sun, Yao
Zhou, Tieli
Chen, Lijiang
author_facet Zeng, Weiliang
Zhang, Xiaotuan
Liu, Yan
Zhang, Yi
Xu, Mengxin
Wang, Sipei
Sun, Yao
Zhou, Tieli
Chen, Lijiang
author_sort Zeng, Weiliang
collection PubMed
description In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus isolates were collected and subjected to susceptibility testing against eravacycline, omadacycline, and tigecycline using the broth microdilution method. Tetracyclines-resistant (eravacycline/omadacycline/tigecycline-resistant) isolates were selected to elucidate the resistance mechanisms using polymerase chain reaction (PCR), cloning experiment, efflux pump inhibition, and quantitative real-time PCR. The results of the antibacterial susceptibility testing showed that compared with omadacycline, eravacycline and tigecycline had superior antibacterial activity against S. aureus isolates. Among 1,017 S. aureus, 41 tetracyclines-resistant isolates were identified. These resistant isolates possessed at least one tetracycline resistance gene and genetic mutation in the MepRAB efflux pump and 30S ribosome units. A frameshift mutation in mepB was detected in most tetracyclines-resistant strains (except for JP3349) compared with tetracyclines-susceptible (eravacycline/omadacycline/tigecycline-susceptible) strains. This was first shown to decrease susceptibility to omadacycline, but not to eravacycline and tigecycline. After treatment with eravacycline, omadacycline or tigecycline, overexpression of mepA, tet38, tet(K) and tet(L) was detected. Moreover, multi-locus sequence typing showed a major clonal dissemination type, ST5, and its variant ST764 were seen in most tetracyclines-resistant strains. To conclude, eravacycline and tigecycline exhibited better activity against S. aureus including tetracycline-resistant isolates than omadacycline. The resistance to these new generation tetracyclines due to an accumulation of many resistance mechanisms.
format Online
Article
Text
id pubmed-9722764
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97227642022-12-07 In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates Zeng, Weiliang Zhang, Xiaotuan Liu, Yan Zhang, Yi Xu, Mengxin Wang, Sipei Sun, Yao Zhou, Tieli Chen, Lijiang Front Microbiol Microbiology In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus isolates were collected and subjected to susceptibility testing against eravacycline, omadacycline, and tigecycline using the broth microdilution method. Tetracyclines-resistant (eravacycline/omadacycline/tigecycline-resistant) isolates were selected to elucidate the resistance mechanisms using polymerase chain reaction (PCR), cloning experiment, efflux pump inhibition, and quantitative real-time PCR. The results of the antibacterial susceptibility testing showed that compared with omadacycline, eravacycline and tigecycline had superior antibacterial activity against S. aureus isolates. Among 1,017 S. aureus, 41 tetracyclines-resistant isolates were identified. These resistant isolates possessed at least one tetracycline resistance gene and genetic mutation in the MepRAB efflux pump and 30S ribosome units. A frameshift mutation in mepB was detected in most tetracyclines-resistant strains (except for JP3349) compared with tetracyclines-susceptible (eravacycline/omadacycline/tigecycline-susceptible) strains. This was first shown to decrease susceptibility to omadacycline, but not to eravacycline and tigecycline. After treatment with eravacycline, omadacycline or tigecycline, overexpression of mepA, tet38, tet(K) and tet(L) was detected. Moreover, multi-locus sequence typing showed a major clonal dissemination type, ST5, and its variant ST764 were seen in most tetracyclines-resistant strains. To conclude, eravacycline and tigecycline exhibited better activity against S. aureus including tetracycline-resistant isolates than omadacycline. The resistance to these new generation tetracyclines due to an accumulation of many resistance mechanisms. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9722764/ /pubmed/36483205 http://dx.doi.org/10.3389/fmicb.2022.1043736 Text en Copyright © 2022 Zeng, Zhang, Liu, Zhang, Xu, Wang, Sun, Zhou and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Zeng, Weiliang
Zhang, Xiaotuan
Liu, Yan
Zhang, Yi
Xu, Mengxin
Wang, Sipei
Sun, Yao
Zhou, Tieli
Chen, Lijiang
In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
title In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
title_full In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
title_fullStr In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
title_full_unstemmed In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
title_short In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
title_sort in vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical staphylococcus aureus isolates
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722764/
https://www.ncbi.nlm.nih.gov/pubmed/36483205
http://dx.doi.org/10.3389/fmicb.2022.1043736
work_keys_str_mv AT zengweiliang invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT zhangxiaotuan invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT liuyan invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT zhangyi invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT xumengxin invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT wangsipei invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT sunyao invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT zhoutieli invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates
AT chenlijiang invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates